Emily Schultz

790 total citations · 1 hit paper
10 papers, 657 citations indexed

About

Emily Schultz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Emily Schultz has authored 10 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Emily Schultz's work include Advanced Breast Cancer Therapies (5 papers), Breast Cancer Treatment Studies (4 papers) and HER2/EGFR in Cancer Research (2 papers). Emily Schultz is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Breast Cancer Treatment Studies (4 papers) and HER2/EGFR in Cancer Research (2 papers). Emily Schultz collaborates with scholars based in United States, Canada and Puerto Rico. Emily Schultz's co-authors include Steven Henikoff, C. Michael McCallum, Timothy M. Rose, Shmuel Pietrokovski, Erik S. Knudsen, Ellis Levine, Tracey L. O’Connor, Agnieszka K. Witkiewicz, Kristopher Attwood and Stephen B. Edge and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Emily Schultz

7 papers receiving 637 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences

1998 605 citations Timothy M. Rose, Emily Schultz et al. Nucleic Acids Research profile →

Peers

Countries citing papers authored by Emily Schultz

Since Specialization

Citations

This map shows the geographic impact of Emily Schultz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Schultz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Schultz more than expected).

Fields of papers citing papers by Emily Schultz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Schultz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Schultz. The network helps show where Emily Schultz may publish in the future.

Co-authorship network of co-authors of Emily Schultz

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Schultz. A scholar is included among the top collaborators of Emily Schultz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Schultz. Emily Schultz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant 2025 ·Familial Cancer ·(unknown), Christos Fountzilas, (unknown), Emily Schultz, (unknown), Erik S. Knudsen, Agnieszka K. Witkiewicz, Kenan Onel	0
2	Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer 2025 ·Oncogene ·Agnieszka K. Witkiewicz, (unknown), Emily Schultz, (unknown), Tracey L. O’Connor, Ellis Levine, Erik S. Knudsen	0
3	Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer 2025 ·npj Breast Cancer ·(unknown), Emily Schultz, Jianxin Wang, (unknown), (unknown), Erik S. Knudsen, Agnieszka K. Witkiewicz	1
4	Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy 2024 ·Cancers ·(unknown), Emily Schultz, (unknown), Tracey L. O’Connor, Ellis Levine, Erik S. Knudsen, Agnieszka K. Witkiewicz	2
5	Determinants of response to CDK4/6 inhibitors in the real-world setting 2023 ·npj Precision Oncology ·Agnieszka K. Witkiewicz, Emily Schultz, Jianxin Wang, (unknown), Ellis Levine, Tracey L. O’Connor, Erik S. Knudsen	16
6	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center 2022 ·The Oncologist ·Erik S. Knudsen, Emily Schultz, (unknown), Kristopher Attwood, Stephen B. Edge, Tracey L. O’Connor, Ellis Levine, Agnieszka K. Witkiewicz	20
7	UACA locus is associated with breast cancer chemoresistance and survival 2022 ·npj Breast Cancer ·Qianqian Zhu, Emily Schultz, Jirong Long, Janise M. Roh, Emily Valice, Cecile A. Laurent, (unknown), Li Yan, Isaac J. Ergas, Warren Davis, Dilrini K. Ranatunga, Shipra Gandhi, Marilyn L. Kwan, Ping‐Ping Bao, Wei Zheng, Xiao‐Ou Shu, Christine B. Ambrosone, Song Yao, Lawrence H. Kushi	5
8	Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort 2021 ·Blood Advances ·Song Yao, Qianqian Zhu, Peter D. Cole, Kristen E. Stevenson, Marian H. Harris, Emily Schultz, Justine M. Kahn, Elena J. Ladas, Uma H. Athale, Luis A. Clavell, Caroline Laverdière, Jean-Marie Leclerc, Bruno Michon, Marshall A. Schorin, Jennifer Welch, Stephen E. Sallan, Lewis B. Silverman, Kara M. Kelly	8
9	Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes in a prospective cohort of 3,995 patients after a median follow-up of 10 years. 2021 ·Journal of Clinical Oncology ·Song Yao, (unknown), Marilyn L. Kwan, Qianqian Zhu, Janise M. Roh, (unknown), Isaac J. Ergas, Emily Schultz, Ting‐Yuan David Cheng, Warren Davis, Catherine Thomsen, Scarlett Lin Gomez, Christine B. Ambrosone, Lawrence H. Kushi	0
10	Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences breakdown → 1998 ·Nucleic Acids Research ·Timothy M. Rose, Emily Schultz, (unknown), Shmuel Pietrokovski, C. Michael McCallum, Steven Henikoff	605

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact